The systemic absorption of etoposide after intravaginal administration in patients with cervical intraepithelial lesions associated with human papillomavirus infection

Pharmaceutical Research

Volumn 23, Issue 2, 2006, Pages 378-383

  Garcia Lopez P ^a   Coll, M ^b   Cervera, E ^a   Reyes Vermot, L ^b   Torres, M A ^b   Abrego Perez G ^b   Hernandez Pajaro A I ^a   Castaneda Hernandez G ^c   Mohar Betancourt, A ^a,d   Meneses, A ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b Laboratorios Lemery SA de CV   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Etoposide; Human papillomavirus; Intraepithelial dysplasia; Vaginal ovule

Indexed keywords

ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG TISSUE LEVEL; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NAUSEA AND VOMITING; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; WART VIRUS;

ABSORPTION; ADMINISTRATION, INTRAVAGINAL; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMISTRY; ETOPOSIDE; FEMALE; HUMANS; INDICATORS AND REAGENTS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES;

EID: 32544458019     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-005-9142-3     Document Type: Article

References (31)

1. F. X. Bosch 2003 Epidemiology of human papillomavirus infections: new option for cervical cancer prevention Salud Publica Mex. 45 S326 S329
2. A. T. Lorincz 2003 Screening for cervical cancer: new alternatives and research Salud Publica Mex. 45 S376 S387
3. M. Fukushima Y. Yamakawa S. Shimano M. Hashimoto Y. Sawada K. Fujinaga 1990 The physical state of human papillomavirus 16 DNA in cervical carcinoma and cervical intraepithelial neoplasia Cancer 66 2155 2161
4. A. Iwasawa P. Nieminen M. Lehtinen J. Paavoneen 1996 Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction Cancer 77 2275 2279
5. H. Hausen 2000 Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis J. Natl. Cancer Inst. 92 690 698
6. H. Furumoto M. Irahara 2002 Human papilloma virus (HPV) and cervical cancer J. Med. Investig. 49 124 133
7. M. M. Holmes S. H. Weaver S. T. Vermillion 1999 A randomized, double-blind, placebo-controlled trial of 5-fluoruracil for the treatment of cervicovaginal human papillomavirus Infect. Dis. Obstet. Gynecol. 7 186 189
8. Y. Liu A. [tmp] McKalip B. Herman 2000 Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation J. Cell. Biochem. 78 334 349
9. G. L. Chen L. Yang T. C. Rowe B. D. Halligan K. M. Tewey L. F. Liu 1984 Nonintercalitive antitumor drugs interfere with the breakage reunion reaction of mammalian DNA topoisomerase II J. Biol. Chem. 259 13560 13566
10. M. Sioud P. Forterre A. M. de Recondo 1987 Effects of the antitumor drug VP16 (etoposide) on the archaebacterial. Halobacterium GRB1.7 Kb plasmid in vivo Nucleic Acids Res. 15 8217 8234
11. J. M. Henwood R. N. Brogden 1990 Etoposide: a review of itspharmacodynamic and pharmacokinetics properties and therapeutic potential in combination chemotherapy of cancer Drugs 39 438 490
12. D. Busse G. Wurthwein C. Hinske G. Hempel M. F. Fromm M. Eichelbaum H. K. Kroemer F. W. Busch 2002 Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration Naunyn-Schmiedebergs Arch. Pharmacol. 366 218 225
13. A. Ballestrero A. Rubagotti P. Stura F. Ferrando D. Amoroso M. Rinaldini P. Sismondi F. Genta M. Mesiti F. Brema F. Patrone F. Boccardo GROETA (Italian Breast Cancer Adjuvant study) 2001 Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5 year results of a pilot trial Oncology 60 221 227
14. H. Kobayashi Y. Kawashima 1989 A case of recurrent uterine cervical cancer successfully treated with etoposide Gan To Kagaku Ryoho 16 3279 3282
15. M. Ikeda K. Noda M. Hiura T. Tamaya M. Ozaki M. Hatae M. Ozawa T. Yamabe K. Tanaka R. Izumi H. Okada Y. Ogita H. Hoshiai 1998 Late phase II trial oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group-Cervical Cancer Group Gan To Kagaku Ryoho 25 2249 2257
16. K. Noda K. Tanaka M. Ozaki K. Hirabayasi K. Hasegawa I. Nishiya M. Yakushiji R. Izumi Y. Tomoda Y. Ogita H. Sugimori T. Yamabe R. Kudo A. Yajima Y. Terashima S. Fujii Y. Suzuoki H. Okada I. Kono K. Ochiai T. Yamamoto M. Ikeda M. Umesaki T. Saito H. Niitani 1998 Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group-Cervical-Ovarian Cancer Group Gan To Kagaku Ryoho 25 2061 2068
17. P. G. Rose J. A. Blessing L. Van S. Waggonner 1998 Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study Gynecol. Oncol. 70 263 266
18. F. L. Meyskens E. Surwit T. E. Moon J. M. Childers J. R. Davis R. T. Dorr C. S. Johnson D. S. Alberto 1994 Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial J. Natl. Cancer Inst. 86 539 543
19. M. Maiman D. H. Watts J. Anderson P. Clax M. Merino M. A. Kendall 1999 Vaginal 5-fluoruracil for high-grade cervical dysplasia in human immunodeficiency virus infection; a randomized trial Obstet. Gynecol. 94 954 961
20. M. M. Alper B. N. Barwin W. M. [tmp] McLean I. J. [tmp] McGilveray S. Sved 1985 Systemic absorption of metronidazole by the vaginal route Obstet. Gynecol. 65 781 784
21. C. Hoffman N. Focke G. Franke M. Zschiesche W. Siegmund 1995 Comparative bioavailability of metronidazole formulations (Vagimid) after oral and vaginal administration Int. J. Clin. Pharmacol. Ther. 33 232 239
22. J. Pérez-Urizar Y. F. Picazo B. Navarro-González F. J. Flores-Murrieta G. Castañeda-Hernández 1996 A new rapid and economic high performance liquid chromatographic assay with electrochemical detection for determination of etoposide (VP16) in human plasma samples J. Liq. Chromatogr. Relat. Technol. 19 939
23. Estadísticas de Mortalidad en México: muertes registradas en el año 2002. Salud Publica Mex. 46:169-185 (2004).
24. K. Bodner B. Bodner-Adler F. Wierrani O. Kimberger C. Denk W. Grunberger 2002 Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis Anticancer Res. 22 3733 3736
25. K. Nakayama Y. Sano Y. Endo H. Sato T. Ohyama M. Yamaguchi 1992 Clinical studies on intravaginal administration of CDDP for dysplasia, carcinoma in situ and microinvasive carcinoma of the uterine cervix Nippon Sanka Fujinka Gakkai Zasshi 44 208 214
26. J. L. Gonzalez-Sanchez G. Flores-Murrieta J. Chavez-Brambilia J. M. Deolarte-Manzano A. F. Andrade-Manzano 2002 Topical 5-Fluoruracil for treatment of vaginal intraepithelial neoplasms Ginecol. Obstet. Mex. 70 244 247
27. M. L. Slevin P. I. Clark S. P. Joel S. Malik R. J. Osborne W. M. Gregory D. G. Lowe R. H. Reznek P. F. Wrigley 1989 A randomised trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer J. Clin. Oncol. 7 1333 1340
28. P. I. Clark M. L. Slevin S. P. Joel R. J. Osborne D. I. Talbot P. W. Johnson R. Reznek T. Masud W. Gregory P. F. Wrigley 1994 A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity J. Clin. Oncol. 12 1427 1435
29. P. I. Clark S. P. Joel M. L. Slevin 1989 A pharmacokinetics hypothesis for the clinical efficacy of etoposide in small-cell lung cancer Proc. ASCO 8 66
30. J. D. Jonkman-de Vries H. Rosing O. van Tellingen C. Neef A. C. Dubbelman A. Bult W. W. ten Bokkel-Huinink B. G. Taal J. H. Beijnen 1995 Pharmacokinetics of etoposide after oral and intravenous administration in patients with gastric carcinoma Clin. Drug Investig. 10 86
31. J. L. Aguilar-Ponce Y. Flores-Picazo J. Pérez-Urizar G. Castañeda-Hernández J. W. Zinser-Sierra A. Dueñas-Gonzalez E. Calderon-Flores B. A. Segura-Pacheco J. de la Garza-Salazar 1999 Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmaeconomic perspectives Arch. Med. Res. 30 212 215